WEBULL
News
ORYZF
3.030
NaN%
--
Oryzon Genomics announces patent grant decision in Mexico
TipRanks · 5d ago
Oryzon Genomics receives EMA approval for Phase II study of iadademstat
TipRanks · 02/24 13:24
Oryzon Genomics appoints Rolando Gutierrez-Esteinou as CMO, CNS Programs
TipRanks · 02/12 13:21
Oryzon Genomics management to meet with Maxim
TipRanks · 02/11 16:45
Oryzon Genomics announces first patient dosed in Phase Ib iadademstat study
TipRanks · 02/09 13:05
Oryzon Genomics receives Decision to Grant from Japanese Patent Office
TipRanks · 02/02 13:16
Oryzon Genomics receives Decision to Grant from Japanese Patent Office
TipRanks · 12/22/2025 13:15
Oryzon Genomics announces results of Extraordinary General Shareholders’ meeting
TipRanks · 12/15/2025 13:55
Oryzon Genomics presents data for iadademstat combinations in AML
TipRanks · 12/09/2025 13:10
Oryzon Genomics S.A. GAAP EPS of $0.01
Seeking Alpha · 11/07/2025 19:37
Weekly Report: what happened at ORYZF last week (0908-0912)?
Weekly Report · 09/15/2025 10:48
Weekly Report: what happened at ORYZF last week (0901-0905)?
Weekly Report · 09/08/2025 10:50
Weekly Report: what happened at ORYZF last week (0825-0829)?
Weekly Report · 09/01/2025 10:46
Weekly Report: what happened at ORYZF last week (0818-0822)?
Weekly Report · 08/25/2025 10:54
Weekly Report: what happened at ORYZF last week (0811-0815)?
Weekly Report · 08/18/2025 10:48
Weekly Report: what happened at ORYZF last week (0804-0808)?
Weekly Report · 08/11/2025 10:54
Weekly Report: what happened at ORYZF last week (0728-0801)?
Weekly Report · 08/04/2025 10:56
Weekly Report: what happened at ORYZF last week (0721-0725)?
Weekly Report · 07/28/2025 10:57
Weekly Report: what happened at ORYZF last week (0714-0718)?
Weekly Report · 07/21/2025 10:48
Weekly Report: what happened at ORYZF last week (0707-0711)?
Weekly Report · 07/14/2025 10:56
More
Webull provides a variety of real-time ORYZF stock news. You can receive the latest news about Oryzon Genomics through multiple platforms. This information may help you make smarter investment decisions.
About ORYZF
Oryzon Genomics SA, is a Spain-based clinical phase biopharmaceutical company, which discovers and develops drugs based on epigenetics for the treatment of oncological and neurological diseases. Its compounds in clinical development include iadademstat (ORY-lOOl), an LSD1 inhibitor that is in Phase II trials for the treatment of acute myeloid leukemia and small cell lung cancer; and vafidemstat (ORY-2001), an LSD1 inhibitor optimized for the Central Nervous System (CNS), in multiple Phase II clinical trials for the treatment of CNS and psychiatric illnesses. The Company also has ORY-3001, in preclinical development for the treatment of non-oncological diseases and has additional programs to develop inhibitors against other epigenetic targets.